Epirubicin Hydrochloride USP \n \nComposition: Epiruba- 50:?Each vial contains Epirubicin Hydrochloride USP 50 mg solution for injection. \n \nIndications:?Epirubicin Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. \n \nDosage and Administration:?When possible, to reduce the risk of developing cardiotoxicity in patients receiving Epirubicin after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as Trastuzumab, Epirubicin-based therapy should be delayed until the other agents have cleared from the circulation. Epirubicin Injection should be administered by intravenous infusion. Epirubicin is given in repeated 3-to 4-week cycles. The total dose of Epirubicin may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. \n \nRecommended Dose:?The recommended dose of Epirubicin is 100 to 120 mg/m?. The following regimens are recommended: \n
CEF-120: | \nCyclophosphamide | \n75 mg/m? PO D 1-14 | \n
Epirubicin | \n60 mg/m? IV D 1, 8 | \n|
5-Fluorouracil | \n500 mg/m? IV D 1, 8 | \n|
Repeated every 28 days for 6 cycles | \n||
FEC-100: | \n5-Fluorouracil | \n500 mg/m? | \n
Epirubicin | \n100 mg/m? | \n|
Cyclophosphamide | \n500 mg/m? | \n
Your purchase will delivered in 1 shipment
Your shopping bag is empty. Start shopping now.